BTG revises annual revenue forecast higher

Healthcare company BTG said on Thursday it has delivered robust full-year results driven by sales across its speciality pharmaceuticals and licensing and biotechnology divisions.

Healthcare company BTG said on Thursday it has delivered robust full-year results driven by sales across its speciality pharmaceuticals and licensing and biotechnology divisions.

The group expects revenue of £230m for the year ended March 31st 2013, according to a trading update ahead of the annual financial statement.

Royalties from products including prostate cancer treatment Zytiga have helped boost results since January when revenue was pegged between £205m to £215m.

Results were also bolstered by favourable exchange rate movements and an agreement of a final sum relating to the discontinued CytoFab programme for treatment of severe sepsis.

Second stage trials of CytoFab - an experimental medicine owned by BTG but licensed to AstraZeneca - were ceased last August after the drug failed significantly to aid patients.

On the flip side, the company successfully completed the US phase two trial programme for Varisolve and submission of a new drug application seeking approval of PEM as a comprehensive treatment to improve the symptoms and appearance of varicose veins.

BTG also in the US launched Voraxaze (glucarpidase), a treatment for life-threatening toxicity in patients with renal impairment who are receiving high-dose methotrexate therapy.

Progress was made towards the submission of humanitarian device exemption applications in the US for the novel pre-loaded Precision Bead and Paragon Bead for use in uveal melanoma liver metastases and intrahepatic cholangiocarcinoma respectively.

"There has been good progress across the business," Chief Executive Louise Makin said.

"Our specialty pharmaceuticals and licensing and biotechnology businesses continue to give us a strong financial underpin. We have a clear strategy to create further value from the cash we are generating, by conducting studies to expand the uses of our interventional oncology products and through the acquisition of complementary products."

RD

Recommended

Get healthy returns from these three healthcare stocks
Share tips

Get healthy returns from these three healthcare stocks

Professional investor Paul Major of the BB Healthcare Trust highlights three of his favourite healthcare stocks.
25 Oct 2021
Share tips of the week – 22 October
Share tips

Share tips of the week – 22 October

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
22 Oct 2021
Three dividend stocks from the dynamic Asia/Pacific region
Share tips

Three dividend stocks from the dynamic Asia/Pacific region

Professional investor Sat Duhra of the Henderson Far East Income investment trust highlights three of his favourite stocks.
18 Oct 2021
Share tips of the week – 15 October
Share tips

Share tips of the week – 15 October

MoneyWeek’s comprehensive guide to the best of this week’s share tips from the rest of the UK's financial pages.
15 Oct 2021

Most Popular

Properties for sale for around £1m
Houses for sale

Properties for sale for around £1m

From a stone-built farmhouse in the Snowdonia National Park, to a Victorian terraced house close to London’s Regent’s Canal, eight of the best propert…
15 Oct 2021
How to invest as we move to a hydrogen economy
Energy

How to invest as we move to a hydrogen economy

The government has started to roll out its plans for switching us over from fossil fuels to hydrogen and renewable energy. Should investors buy in? St…
8 Oct 2021
Emerging markets: the Brics never lived up to their promise – but is now the time to buy?
Emerging markets

Emerging markets: the Brics never lived up to their promise – but is now the time to buy?

Twenty years ago hopes were high for Brazil, Russia, India and China – the “Brics” emerging-market economies. But only China has beaten expectations. …
18 Oct 2021